Live Webinar: Optimizing IBD Management with Fecal Calprotectin - From Diagnosis to Monitoring
Inflammatory bowel disease (IBD) is a condition that significantly impacts quality of life, highlighting the necessity for prompt and efficient intervention to improve patient outcomes. Emphasizing a "treat-to-target" methodology, this webinar underscores the critical role of non-invasive monitoring methods, particularly fecal calprotectin monitoring, in guiding treatment adjustments and achieving therapeutic goals. We will delve into how this non-invasive tool, among others, aids in the consistent evaluation of treatment efficacy and disease progression, especially within the frameworks of Crohn’s disease and ulcerative colitis management.
- The significance of fecal calprotectin as a non-invasive biomarker in the diagnosis, prognosis, and monitoring of IBD.
- A review of the current non-invasive monitoring tools and their role in implementing "treat-to-target" strategies effectively.
- The importance of and approach to biomarker monitoring during critical disease stages in both Crohn's disease and ulcerative colitis.
- Pragmatic tips for successful implementation of fecal calprotectin monitoring in routine clinical practice.
Presenter: Dr. Benjamin Click, University of Colorado, Department of Gastroenterology
Benjamin Click, MD earned his undergraduate and medical degrees from the University of Virginia and completed his internal medicine and gastroenterology training at UPMC in Pittsburgh, PA where he received an NIH T32 training award and served as chief fellow. He simultaneously earned a Masters’ in Clinical Research from the University of Pittsburgh. Dr. Click then served as Staff Gastroenterologist at Cleveland Clinic from 2018 to 2022 before joining the faculty at the University of Colorado in 2022 as Assistant Professor of Medicine. He is board-certified in Internal Medicine and Gastroenterology. He has served as principal investigator on multiple clinical trials in IBD. Dr. Click’s personal interests include hiking with his family, skiing, reading, playing guitar, and exploring Colorado activities.
Host: Bethany Bell, PhD
Bethany Bell, PhD is the Vice President of Global Business Development and joined ALPCO in 2011. Since joining ALPCO, a notable accomplishment for her is the pivotal role she played during the development and launch of ALPCO’s first Class II 510k cleared product for the detection of fecal calprotectin; facilitating the IRB process, driving clinical trial management, training >15 recruitment/testing sites, and developing content and campaigns for market launch. Following this launch, Bethany has driven ALPCO’s strategic product focus into the gastroenterological space earning the organization the reputation of market leader within North America for high quality GI stool-based biomarker assays. Bethany holds her PhD from Dartmouth College, which she earned following several years of study involving the sensitization of leukemia and lymphoma through combination chemotherapy.
